Blood cancers, Hodgkin lymphoma, Lymphoma
Results
Phase 2
This trial looked at a drug called pembrolizumab. It was for people with Hodgkin lymphoma that had:
come back after treatment ()
continued to grow despite treatment ()
Recruitment start: 22 October 2015
Recruitment end: 31 March 2016
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor John Radford
Merck Sharp & Dohme Ltd
Experimental Cancer Medicine Centre (ECMC)
Last reviewed: 19 Apr 2018
CRUK internal database number: 13432
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
